Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Borchmann

Showing results (201-210 of 252) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Volker Diehl, et al.
Blood Advances|June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCLRakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
JAMA Oncology|May 1, 2020
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL TrialPaul J Bröckelmann, Helen Goergen, Ulrich Keller, et al.
Blood|September 2, 2008
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphomaCarsten Kobe, Markus Dietlein, Jeremy Franklin, et al.
Leukemia|June 11, 2021
Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPPRon D Jachimowicz, Wolfram Klapper, Gunther Glehr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2012
Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trialsKarolin Behringer, Horst Mueller, Helen Goergen, et al.
British Journal of Haematology|August 28, 2015
Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study GroupPaul J Bröckelmann, Helen Goergen, Michael Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trialHans Theodor Eich, Volker Diehl, Helen Görgen, et al.
Blood|February 9, 2026
MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assayJan-Michel Heger, Julia Mattlener, Helen Kaul, et al.
Blood Advances|February 20, 2020
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphomaRichard T Maziarz, Edmund K Waller, Ulrich Jaeger, et al.
Pageof 26

Showing results (201-210 of 252) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Volker Diehl, et al.
Blood Advances|June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCLRakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
JAMA Oncology|May 1, 2020
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL TrialPaul J Bröckelmann, Helen Goergen, Ulrich Keller, et al.
Blood|September 2, 2008
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphomaCarsten Kobe, Markus Dietlein, Jeremy Franklin, et al.
Leukemia|June 11, 2021
Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPPRon D Jachimowicz, Wolfram Klapper, Gunther Glehr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2012
Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trialsKarolin Behringer, Horst Mueller, Helen Goergen, et al.
British Journal of Haematology|August 28, 2015
Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study GroupPaul J Bröckelmann, Helen Goergen, Michael Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trialHans Theodor Eich, Volker Diehl, Helen Görgen, et al.
Blood|February 9, 2026
MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assayJan-Michel Heger, Julia Mattlener, Helen Kaul, et al.
Blood Advances|February 20, 2020
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphomaRichard T Maziarz, Edmund K Waller, Ulrich Jaeger, et al.
Pageof 26